Discussion: Dosage, effects, applications, price, and additional information
Nemluvio, a brand-name prescription medication, has been approved by the FDA to treat eczema (atopic dermatitis) in adults and children aged 12 years and older, as well as prurigo nodularis in adults. This biologic drug, produced by the company Galderma, belongs to the class of interleukin-31 receptor blockers.
Nemluvio works by blocking a protein in the body called interleukin-31 (IL-31). This action helps reduce inflammation and itching associated with eczema and prurigo nodularis. It is important to note that Nemluvio is not a cure for these conditions, and symptoms may return if treatment is stopped.
The dosage and frequency of Nemluvio vary based on the condition being treated and the person's weight. For eczema, the typical starting dose is two injections (60 mg), followed by one injection (30 mg) every 4 weeks, and potentially one injection every 8 weeks if the skin is almost clear after 16 weeks of treatment. For prurigo nodularis, the typical starting dose is two injections (60 mg), followed by an ongoing dose that depends on the person's body weight.
It is administered via subcutaneous injection, and comes in a prefilled, single-use injection pen containing powder and sterile water that mix inside the pen to form a liquid solution.
While Nemluvio is not known to interact with other medications, herbs, supplements, foods, or alcohol, there are certain precautions to consider. Live vaccines, such as those for chickenpox or measles, mumps, and rubella, should not be received during treatment with Nemluvio. The safety and effectiveness of Nemluvio during pregnancy and while breastfeeding are also unknown.
Side effects of Nemluvio can include headache or migraine, injection site reactions, joint pain, muscle pain, hives, skin rashes, and allergic reactions. In the event of an overdose or severe side effects, contact a healthcare professional immediately.
For those who may need financial or insurance assistance with Nemluvio, a program called Galderma Patient Service is available. This program is designed to help eligible patients access and afford their medication.
In conclusion, Nemluvio offers a new treatment option for individuals suffering from eczema and prurigo nodularis. As with any medication, it is important to discuss its benefits and potential risks with a healthcare provider before starting treatment.
